Navigation Links
Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
Date:2/28/2008

Nordic Biotech II K/S and MPM BioVentures close on additional $6 million

investment on top of $75 million previous investment

AMSTERDAM, Netherlands and ALAMEDA, Calif., Feb. 28 /PRNewswire/ -- Arriva Pharmaceuticals, a biopharmaceutical company focused on developing anti- inflammatory therapies for treating respiratory diseases, completed a financing of 6 million USD led by new Investor Nordic Biotech II K/S and with participation by MPM BioVentures. Since its founding in 1997, Arriva has now raised a total of 81 million USD.

"Key financing from Nordic Biotech II KS and from our earlier lead investor, MPM Capital, allows us to continue the development of recombinant alpha-one antitrypsin for hereditary emphysema," said Sue Preston, CEO, Arriva Pharmaceuticals. "With a committed, experienced management team, we are now focused on the clinical development of our lead and pipeline products."

"We are investing in the clear value we see in Arriva's late-stage inhaled protein rAAT, a replacement product for the treatment of hereditary emphysema," said Florian Schonharting, partner of Nordic Biotech. "Our goal with Arriva is to provide financing and through board participation, help the company become a recognized, fully integrated biotech concern," added Christian Hansen, partner of Nordic Biotech.

"MPM has been a supporter of Arriva and the company's mission since 2002," said Ansbert Gadicke, General Partner, MPM Capital. "We continue to believe that there is significant potential in the company's respiratory product pipeline and are involved in this financing because we anticipate that Arriva will successfully capitalize on its IP and other assets."

About Arriva:

Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, chronic obstructive pulmonar
'/>"/>

SOURCE Arriva Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)..., , CHICAGO, Nov. 29 This... (RSNA) Scientific Assembly and Annual Meeting, FU...nce into the advanced visualization space with the...lding on its core strength in image processing by ... for both general radiographic and cardiovascular ...
(Date:11/27/2009)..., , Another option to prevent illne...,, SILVER SPRING, Md., Nov. 27 /PRNewswire-USNe...oday approved Agriflu for people ages 18 years and...s subtypes A and B. ,, (Logo: http://www.new...iflu, manufactured by Novartis Vaccines and Diagno...
(Date:11/27/2009)..., , CHICAGO, Nov. 27 ...ica (RSNA) annual meeting starting Sunday, Royal P...te a new range of healthcare imaging and informati...rities of patients and care providers, by deliveri...esire for value, modular price points and easy upg...
Breaking Medicine Technology:FUJIFILM Enters Advanced Visualization Market 2FUJIFILM Enters Advanced Visualization Market 3FUJIFILM Enters Advanced Visualization Market 4FDA Approves Agriflu Seasonal Influenza Vaccine 2Philips Helps Hospitals Strike Balance Between Innovation and Value 2Philips Helps Hospitals Strike Balance Between Innovation and Value 3Philips Helps Hospitals Strike Balance Between Innovation and Value 4Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 60856 1Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 60856 2Lockton and Concentra Working Together to Lower Healthcare Costs for Employers 60856 3Caraco Pharmaceutical Laboratories Ltd Markets Generic Acular 28R 29 Ophthalmic Solution 6058 1Caraco Pharmaceutical Laboratories Ltd Markets Generic Acular 28R 29 Ophthalmic Solution 6058 2New Smells Etched in Brain 3A Study 60854 1New Smells Etched in Brain 3A Study 60854 2
...lorida,Technology, Research and Scholarship Board ...rcher Dr. Herbert Weissbach, distinguished,profess...y and,Biotechnology in the Charles E. Schmidt Coll...294 as part of the State University Research,Comme...URECAG was,established by the Florida Legislature ...
...rporation,(Amex: CVM ) announced today that it pr...s Evans conference on Immunogenicity in Amsterdam....r Vice President of Research,Cellular Immunology o...ritis vaccine CEL-2000 prevents or retards the per...s in an animal model of the disease. These new,fin...
Other Medicine Technology:Major State Grant Accelerates Research and Development of Novel Cancer Therapy 2Major State Grant Accelerates Research and Development of Novel Cancer Therapy 3Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 2Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 3Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis 4
(Date:11/27/2009)...nce, Nov. 27 Team Garmin-Slipstrea...dicated to ethical sporting and developing the nex... that it will become Team Garmin-Transitions with ...or of the team. Transitions Optical is the world,s...g the most advanced photochromic technology in the...
(Date:11/27/2009)...oldings has announced that it has become a nationa...largest nonprofit organizations dedicated to arthr... Delray Beach, FL (Vocus) Novem...HO), a company specializing in the marketing and r..., has announced today that is has become a nationa...
(Date:11/27/2009)... medical, economic burdens, study predicts , ...ber of people with diabetes in the United States i... study predicts. , That would bring the total b...se, up from 23.7 million today. , , At the same ...ll triple, the study also warns, rising from an es...
(Date:11/27/2009)...lth™ announced today that Spectrum Health (G...Enterprise orthopedic templating solution and its ... (PRWEB) November 27, 2009 -- Voyant H...(Grand Rapids, Michigan) has licensed its TraumaCa...s TraumaCad Extend workflow solution, to allow its...
(Date:11/27/2009)... manufacturers who use medical load cells at the h...ars by bringing in technology partner Flintec earl...-active medical manufacturers are calling in Flint... projects, ensuring that progress will not be cons...y outdated technology. , ...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...dy published in the December issue of Arthritis an...llagen (CII) could have a vital role in the pathog...l inflammatory // joint condition. This protei...ifies itself and then proceeds to systematically d...
... Virginia - Researchers at the Virginia Commonweal...plasma lipoprotein in patients with advanced perio...k of heart disease in these patients. // Peri...ases including diabetes and cardiovascular disease...
...velling Asia and causing havoc the bird flu has sp...es have been detected in Ukraine. This has sen... // To ascertain the severity of the flu tes... called for by the Ukrainian president in some par...
...h sector of England has both doctors and nurses of... to be almost 20 percent.// The National Health S...a, from the Birmingham Children's Hospital, in the...n's health charity WellChild launched the competit...
...ity of Cincinnati (UC) research team comprising Sc...ws negative effect in brain tissue// 'at surprisin...e new studies are also the first to show that oest...eproductive functions,' 'BPA molecules are l...
...dy says that squinting at your computer screens is...ss of lubrication leading to eye strain, irritatio...niversity say that the less people blink the more ...te go way down," said lead researcher James Sheedy...
Other Medicine News:Health News:Severe Gum Disease Triples Heart Disease Risk 2Health News:Food packaging with Bisphenol A damages the brain 2
Sterilized TowerPack Refill System D200
Finntip Wide 10-200ul, Sterile
Finntip 200 Ext (Sterile)
MBP 200MicroPoint Design
Medicine Products: